Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2021 · 10-Q
Revenue$6.50M$6.50M+13.6% vs Q1 2020 Net Income-$56.73M-$56.73MN/M vs Q1 2020 EPS Diluted-$0.86-$0.86N/M vs Q1 2020 Operating Income-$56,883,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$49,563,000N/M Margins · derivedOperating margin-875.3%−60.7 pt vs Q1 2020
Net margin-872.9%−213.7 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end